In support of the European Society of Medical Oncology’s (ESMO) strategy to educate medical oncologists, other physicians in cancer care, as well as translational investigators about BRCA across tumor types, Judith Balmaña, Principal Investigator of VHIO’s High Risk & Cancer Prevention Group, was filmed here at VHIO and across the Vall d´Hebron Barcelona Hospital Campus to deliver a masterclass on the role and relevance of the BRCA1 and BRCA 2 proteins in cancer risk assessment, early detection and cancer prevention, and the implication of BRCA deficiency as a predictive biomarker for targeted therapies in different tumor types.
Invited by ESMO’s Translational Research and Personalized Medicine Working Group, Judith was selected for her renowned expertise and international standing, both as a leading medical oncologist and clinical investigator, in identifying, translating and clinically developing therapeutic strategies for tumors associated with hereditary genetic alterations.
This ESMO Group, formed to promote high-quality translational research in oncology and devise translatoian research-related content for the Society’s educational programs, is chaired by Fabrice André, Insitut Gustave Roussy (Paris, France), and comprises thirteen expert Committee Members, including VHIO’s Joan Seoane, Director of Translational Research, and Joquin Mateo, Principal Investigator of our Prostate Cancer Translational Research Group.
Please click on the image below to access this educational ESMO video:
###
